Galunisertib Combined With Capecitabine in Advanced CRC With PM
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a two-center open-label non-randomized proof of principle study consisting of a
dose-finding part (phase I) and phase II study with Simon two-stage design investigating the
anti-tumor activity of the combination of capecitabine and galunisertib in patients with
colorectal cancer with peritoneal metastases.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborator:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)